Australia markets closed

NovoCure Limited (038.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
14.11-0.41 (-2.82%)
As of 04:51PM CET. Market open.

NovoCure Limited

No. 4 The Forum
Second Floor Grenville Street
Saint Helier JE2 4UF
Jersey
44 15 3475 6700
https://www.novocure.com

Sector(s)Healthcare
IndustryMedical Devices
Full-time employees1,453

Key executives

NameTitlePayExercisedYear born
Mr. William F. DoyleExecutive Chairman1.41MN/A1962
Mr. Asaf DanzigerCEO & Director1.57MN/A1966
Ms. Ashley CordovaChief Financial Officer861.72k426.42k1979
Mr. Wilhelmus C. M. GroenhuysenChief Operating Officer929.35kN/A1958
Mr. Frank LeonardExecutive VP & President of Novocure Oncology667.57k421.98kN/A
Prof. Yoram Palti M.D., Ph.D.Founder & CTO260.82kN/A1938
Dr. Moshe Giladi Ph.D.Chief Science OfficerN/AN/A1970
Ms. Ingrid GoldbergVP of Investor RelationsN/AN/AN/A
Mr. Barak Ben AryeGeneral CounselN/AN/A1977
Mr. Michael PuriChief Human Resources OfficerN/AN/A1969
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Corporate governance

NovoCure Limited’s ISS governance QualityScore as of 1 March 2024 is 2. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 3; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.